Literature DB >> 27199276

Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.

Michael Wahl1, Martina Descovich1, Erin Shugard1, Dilini Pinnaduwage2, Atchar Sudhyadhom1, Albert Chang1, Mack Roach1, Alexander Gottschalk1, Josephine Chen1.   

Abstract

Stereotactic body radiotherapy for prostate cancer is rapidly growing in popularity. Stereotactic body radiotherapy plans mimic those of high-dose rate brachytherapy, with tight margins and inhomogeneous dose distributions. The impact of interfraction anatomical changes on the dose received by organs at risk under these conditions has not been well documented. To estimate anatomical variation during stereotactic body radiotherapy, 10 patients were identified who received a prostate boost using robotic stereotactic body radiotherapy after completing 25 fractions of pelvic radiotherapy with daily megavoltage computed tomography. Rectal and bladder volumes were delineated on each megavoltage computed tomography, and the stereotactic body radiotherapy boost plan was registered to each megavoltage computed tomography image using a point-based rigid registration with 3 fiducial markers placed in the prostate. The volume of rectum and bladder receiving 75% of the prescription dose (V75%) was measured for each megavoltage computed tomography. The rectal V75% from the daily megavoltage computed tomographies was significantly greater than the planned V75% (median increase of 0.93 cm3, P < .001), whereas the bladder V75% on megavoltage computed tomography was not significantly changed (median decrease of -0.12 cm3, P = .57). Although daily prostate rotation was significantly correlated with bladder V75% (Spearman ρ = .21, P = .023), there was no association between rotation and rectal V75% or between prostate deformation and either rectal or bladder V75%. Planning organ-at-risk volume-based replanning techniques using either a 6-mm isotropic expansion of the plan rectal contour or a 1-cm expansion from the planning target volume in the superior and posterior directions demonstrated significantly improved rectal V75% on daily megavoltage computed tomographies compared to the original stereotactic body radiotherapy plan, without compromising plan quality. Thus, despite tight margins and full translational and rotational corrections provided by robotic stereotactic body radiotherapy, we find that interfraction anatomical variations can lead to a substantial increase in delivered rectal doses during prostate stereotactic body radiotherapy. A planning organ-at-risk volume-based approach to treatment planning may help mitigate the impact of daily organ motion and reduce the risk of rectal toxicity.

Entities:  

Keywords:  CyberKnife; IGRT; SABR; SBRT; dosimetry

Mesh:

Year:  2016        PMID: 27199276      PMCID: PMC5616028          DOI: 10.1177/1533034616649495

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  39 in total

1.  Continuous monitoring and intrafraction target position correction during treatment improves target coverage for patients undergoing SBRT prostate therapy.

Authors:  D Michael Lovelock; Alessandra P Messineo; Brett W Cox; Marisa A Kollmeier; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-01-30       Impact factor: 7.038

2.  Daily variations in delivered doses in patients treated with radiotherapy for localized prostate cancer.

Authors:  Patrick A Kupelian; Katja M Langen; Omar A Zeidan; Sanford L Meeks; Twyla R Willoughby; Thomas H Wagner; Sam Jeswani; Kenneth J Ruchala; Jason Haimerl; Gustavo H Olivera
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

3.  A study on planning organ at risk volume for the rectum using cone beam computed tomography in the treatment of prostate cancer.

Authors:  Ramachandran Prabhakar; Richard Oates; Daryl Jones; Tomas Kron; Jim Cramb; Farshad Foroudi; Moshi Geso; Suki Gill
Journal:  Med Dosim       Date:  2014-01-08       Impact factor: 1.482

4.  The intraclass correlation coefficient as a measure of reliability.

Authors:  J J Bartko
Journal:  Psychol Rep       Date:  1966-08

5.  Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.

Authors:  Thomas P Boike; Yair Lotan; L Chinsoo Cho; Jeffrey Brindle; Paul DeRose; Xian-Jin Xie; Jingsheng Yan; Ryan Foster; David Pistenmaa; Alida Perkins; Susan Cooley; Robert Timmerman
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

6.  Intrafractional stability of the prostate using a stereotactic radiotherapy technique.

Authors:  Berit L Madsen; R Alex Hsi; Huong T Pham; Joseph Presser; Laura Esagui; John Corman; Lee Myers; Douglas Jones
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-12-01       Impact factor: 7.038

7.  Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes.

Authors:  Andrew Loblaw; Patrick Cheung; Laura D'Alimonte; Andrea Deabreu; Alexandre Mamedov; Liying Zhang; Colin Tang; Harvey Quon; Suneil Jain; Geordi Pang; Robert Nam
Journal:  Radiother Oncol       Date:  2013-05-03       Impact factor: 6.280

8.  Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.

Authors:  Christopher R King; James D Brooks; Harcharan Gill; Todd Pawlicki; Cristian Cotrutz; Joseph C Presti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-26       Impact factor: 7.038

9.  Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.

Authors:  Shoichi Fukuda; Yuji Seo; Hiroya Shiomi; Yuji Yamada; Toshiyuki Ogata; Masahiro Morimoto; Koji Konishi; Yasuo Yoshioka; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2014-06-23       Impact factor: 2.724

10.  Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.

Authors:  Alan J Katz; Michael Santoro; Fred Diblasio; Richard Ashley
Journal:  Radiat Oncol       Date:  2013-05-13       Impact factor: 3.481

View more
  10 in total

1.  Dosimetric impact of organ at risk daily variation during prostate stereotactic ablative radiotherapy.

Authors:  Lynsey Devlin; David Dodds; Azmat Sadozye; Philip McLoone; Nicholas MacLeod; Carolynn Lamb; Suzanne Currie; Stefanie Thomson; Aileen Duffton
Journal:  Br J Radiol       Date:  2020-01-30       Impact factor: 3.039

2.  Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response.

Authors:  Kyle Wang; Panayiotis Mavroidis; Trevor J Royce; Aaron D Falchook; Sean P Collins; Stephen Sapareto; Nathan C Sheets; Donald B Fuller; Issam El Naqa; Ellen Yorke; Jimm Grimm; Andrew Jackson; Ronald C Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-12-22       Impact factor: 7.038

3.  Monitoring of mechanical errors and their dosimetric impact throughout the course of non-coplanar continuous volumetric-modulated arc therapy.

Authors:  Hideaki Hirashima; Mitsuhiro Nakamura; Yuki Miyabe; Megumi Uto; Kiyonao Nakamura; Takashi Mizowaki
Journal:  Radiat Oncol       Date:  2018-02-14       Impact factor: 3.481

4.  Strict bladder filling and rectal emptying during prostate SBRT: Does it make a dosimetric or clinical difference?

Authors:  David J Byun; Daniel J Gorovets; Lauren M Jacobs; Laura Happersett; Pengpeng Zhang; Xin Pei; Sarah Burleson; Zhigang Zhang; Margie Hunt; Sean McBride; Marisa A Kollmeier; Michael J Zelefsky
Journal:  Radiat Oncol       Date:  2020-10-16       Impact factor: 3.481

5.  Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy.

Authors:  Vickie C Kong; Jennifer Dang; Winnie Li; Inmaculada Navarro; Jerusha Padayachee; Victor Malkov; Jeff Winter; Srinivas Raman; Alejandro Berlin; Charles Catton; Padraig Warde; Peter Chung
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2022-03-02

6.  Adaptive radiation therapy strategies in the treatment of prostate cancer patients using hypofractionated VMAT.

Authors:  Pawel Siciarz; Boyd McCurdy; Nikesh Hanumanthappa; Eric Van Uytven
Journal:  J Appl Clin Med Phys       Date:  2021-11-16       Impact factor: 2.102

Review 7.  Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology.

Authors:  William A Hall; Amar U Kishan; Emma Hall; Himanshu Nagar; Danny Vesprini; Eric Paulson; Uulke A Van der Heide; Colleen A F Lawton; Linda G W Kerkmeijer; Alison C Tree
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

8.  Autosegmentation of the rectum on megavoltage image guidance scans.

Authors:  L E A Shelley; M P F Sutcliffe; K Harrison; J E Scaife; M A Parker; M Romanchikova; S J Thomas; R Jena; N G Burnet
Journal:  Biomed Phys Eng Express       Date:  2019-01-10

9.  Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy.

Authors:  Miriam Eckl; Gustavo R Sarria; Sandra Springer; Marvin Willam; Arne M Ruder; Volker Steil; Michael Ehmann; Frederik Wenz; Jens Fleckenstein
Journal:  Radiat Oncol       Date:  2021-08-04       Impact factor: 3.481

10.  Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis.

Authors:  Stephanie M Yoon; Elaine Luterstein; Fang-I Chu; Minsong Cao; James Lamb; Nzhde Agazaryan; Daniel Low; Ann Raldow; Michael L Steinberg; Percy Lee
Journal:  Cancer Med       Date:  2021-07-20       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.